Literature DB >> 6391757

Endocrinological aspects of obesity.

R Jung.   

Abstract

Throughout this review I have emphasized the role that nutrition plays in determining the endocrine abnormalities often found in obesity. There appears to be no consistent thyroid abnormality. Increased cortisol production and metabolism is found in obesity but is reversible with loss of weight. Androgen production is increased in females and can also be reduced with dieting. On the other hand, total serum testosterone is reduced in males, although free serum testosterone is normal in all but those who are severely obese. Various pituitary abnormalities have also been reported; some are reversible but others apparently are not, although extensive follow-up studies are not available to allow a clear distinction to be made between reversible and non-reversible abnormalities. Insulin resistance, a common feature of obesity, is due to receptor and postreceptor defects but again is a reversible phenomenon. Thus there is little to indicate that obesity depends on some underlying endocrine abnormality but much evidence to suggest that the endocrine changes are secondary to the abnormal nutritional state of the patient. This should be remembered when investigating any obese patient for suspected endocrine pathology.

Entities:  

Mesh:

Year:  1984        PMID: 6391757     DOI: 10.1016/s0300-595x(84)80040-7

Source DB:  PubMed          Journal:  Clin Endocrinol Metab        ISSN: 0300-595X


  6 in total

1.  Dehydroepiandrosterone sulfate levels in women. Relationships with age, body mass index and insulin levels.

Authors:  E Mazza; M Maccario; J Ramunni; C Gauna; A Bertagna; A M Barberis; S Patroncini; M Messina; E Ghigo
Journal:  J Endocrinol Invest       Date:  1999-10       Impact factor: 4.256

2.  The search for a hormonal switch for obesity.

Authors:  C Dieguez; M F Scanlon
Journal:  Br Med J (Clin Res Ed)       Date:  1987-05-30

3.  The influence of chronic administration of the serotonin agonist dexfenfluramine on responsiveness to corticotropin releasing hormone and growth hormone-releasing hormone in moderately obese people.

Authors:  M L Drent; H J Adèr; E A van der Veen
Journal:  J Endocrinol Invest       Date:  1995-11       Impact factor: 4.256

4.  Hypothalamic and pituitary c-Jun N-terminal kinase 1 signaling coordinately regulates glucose metabolism.

Authors:  Bengt F Belgardt; Jan Mauer; F Thomas Wunderlich; Marianne B Ernst; Martin Pal; Gabriele Spohn; Hella S Brönneke; Susanne Brodesser; Brigitte Hampel; Astrid C Schauss; Jens C Brüning
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-15       Impact factor: 11.205

5.  Hypogonadotropic hypogonadism in a patient with morbid obesity.

Authors:  Miguel Angel Mollar Puchades; Rosa Cámara Gómez; Maria Isabel del Olmo García; José Luis Ponce Marco; Raquel Segovia Portolés; Pablo Abellán Galiana; Francisco Piñón Sellés
Journal:  Obes Surg       Date:  2007-08       Impact factor: 4.129

6.  Neutralization of osteopontin inhibits obesity-induced inflammation and insulin resistance.

Authors:  Florian W Kiefer; Maximilian Zeyda; Karina Gollinger; Birgit Pfau; Angelika Neuhofer; Thomas Weichhart; Marcus D Säemann; René Geyeregger; Michaela Schlederer; Lukas Kenner; Thomas M Stulnig
Journal:  Diabetes       Date:  2010-01-27       Impact factor: 9.461

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.